PRospective Observational registry evaluating the Safety and Effectiveness of Orsiro Stent in Chilean patients - ROSES registry. PRospective Observational Registry Evaluating the Safety and Effectivenessof Orsiro Stent in Chilean Patients - ROSES Registry.

MedStar author(s):
Citation: Cardiovascular Revascularization Medicine. 36:65-70, 2022 03.PMID: 34092499Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Cardiovascular Agents | *Coronary Artery Disease | *Drug-Eluting Stents | *Percutaneous Coronary Intervention | *Rosa | Absorbable Implants | Aged | Cardiovascular Agents/ae [Adverse Effects] | Chile | Coronary Artery Disease/th [Therapy] | Drug-Eluting Stents/ae [Adverse Effects] | Humans | Male | Middle Aged | Percutaneous Coronary Intervention/ae [Adverse Effects] | Prosthesis Design | Registries | Time Factors | Treatment OutcomeYear: 2022Local holdings: Available in print through MWHC library: 2002 - presentISSN:
  • 1878-0938
Name of journal: Cardiovascular revascularization medicine : including molecular interventionsAbstract: BACKGROUND: There is little information of the performance of the new generation of stents with bioabsorbable polymers in the Latin-American population. This registry aimed to further validate the safety and efficacy of the Orsiro bioresorbable polymer sirolimus-eluting stent (BPSES) in unselected patients undergoing percutaneous coronary intervention (PCI) in Chilean centers.CONCLUSIONS: The results of the ROSES multicenter registry indicated good clinical outcomes of BPSES Orsiro in all-comers Latin-American patients undergoing PCI, despite the high-risk patients and treated lesions. Copyright (c) 2021 Elsevier Inc. All rights reserved.METHODS: We prospectively enrolled patients undergoing PCI with BPSES in 6 Chilean centers. The primary endpoint was defined as the composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization at 1-year follow-up.RESULTS: From April 2017 to February 2019, n = 520 patients were enrolled in the registry, more frequently male (74.6%), with a mean age of 62.7 +/- 10.8 years-old and a high prevalence of diabetes (40.2%). The clinical presentation was stable angina in 41.1% (n = 214), acute MI in 52.5% (n = 167 [32.1%] ST-elevation MI and n = 106 [20.4%] non-ST-elevation MI) and unstable angina in 6.3% (n = 33). Of 610 treated lesions, 425 (69.7%) were ACC/AHA type B or C lesions. Device and procedural success were achieved in 99.4% and 98.7% of the patients, respectively. The primary endpoint of the study occurred in 4%, primary driven by cardiac death.All authors: Antezana G, Assef V, Cavada G, Garcia-Garcia HM, Giacaman A, Maluenda G, Olmos A, Perez L, Perez O, Pincetti C, Puentes A, Ramirez P, Venegas R, Vergara MJOriginally published: Cardiovascular Revascularization Medicine. 2021 May 27Fiscal year: FY2021Digital Object Identifier: Date added to catalog: 2021-07-19
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 34092499 Available 34092499

Available in print through MWHC library: 2002 - present

BACKGROUND: There is little information of the performance of the new generation of stents with bioabsorbable polymers in the Latin-American population. This registry aimed to further validate the safety and efficacy of the Orsiro bioresorbable polymer sirolimus-eluting stent (BPSES) in unselected patients undergoing percutaneous coronary intervention (PCI) in Chilean centers.

CONCLUSIONS: The results of the ROSES multicenter registry indicated good clinical outcomes of BPSES Orsiro in all-comers Latin-American patients undergoing PCI, despite the high-risk patients and treated lesions. Copyright (c) 2021 Elsevier Inc. All rights reserved.

METHODS: We prospectively enrolled patients undergoing PCI with BPSES in 6 Chilean centers. The primary endpoint was defined as the composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization at 1-year follow-up.

RESULTS: From April 2017 to February 2019, n = 520 patients were enrolled in the registry, more frequently male (74.6%), with a mean age of 62.7 +/- 10.8 years-old and a high prevalence of diabetes (40.2%). The clinical presentation was stable angina in 41.1% (n = 214), acute MI in 52.5% (n = 167 [32.1%] ST-elevation MI and n = 106 [20.4%] non-ST-elevation MI) and unstable angina in 6.3% (n = 33). Of 610 treated lesions, 425 (69.7%) were ACC/AHA type B or C lesions. Device and procedural success were achieved in 99.4% and 98.7% of the patients, respectively. The primary endpoint of the study occurred in 4%, primary driven by cardiac death.

English

Powered by Koha